What we are
WELCOME TO BIOBOHEMIA

Formed in 2006 the BioBohemia brought together perspective scientists into a business structure committed to the development of novel products and procedures for applications in anti-cancer therapy. From the beginning of 2008 the BioBohemia places emphasis on R&D of antigens for cancer vaccines. 

READ MORE

TECHNOLOGY
Our way to help you developing cancer vaccines

Destruction of tumor vasculature integrity by vaccination represents one of the most attractive cancer immunotherapy approaches due to its ability to prevent growth of solid cancers. SANTAVAC ™ – the first antigen composition based on endothelial cell heterogeneity – allows targeting of the tumor vasculature with a high predicted efficacy. These data suggest that use of SANTAVAC ™ as a universal antigenic composition may spur vaccine development activities resulting in a set of therapeutic or prophylactic vaccines against different types of solid cancers. The large-scale implementation of SANTAVAC ™ as antigens suitable for the treatment and prevention of diverse types of cancers is a current aim of BioBohemia.

VIEW MORE

PRODUCTS & SERVICES
Take our antigen composition and prepare own cancer vaccine

SANTAVAC ™ – the first antigenic composition for anti-cancer vaccination based on endothelial cells heterogeneity.

SANTAVAC™ can be mixed with different adjuvants to produce vaccines specific against different types of solid cancers that can be tested in vivo for immunogenicity and safety.

VIEW MORE

PUBLICATIONS
& Patents

30
Oct-2016

7-Com

433-View

OUR PUBLICATIONS

All SANTAVAC™ design activities were published in peer-reviewed journals.

25
Oct-2016

0-Com

272-View

PATENTS

SANTAVAC™ production is protected in main developed countries.